Steinbrecht et al. AMB Expr
(2020) 10:128
Page 12 of 13
Hohorst HJ, Peter G, Struck RF (1976) Synthesis of 4‑hydroperoxy derivatives of
ifosfamide and trofosfamide by direct ozonation and preliminary antitu‑
mor evaluation in vivo. Cancer Res 36(7 PT 1):2278–2281
Javitt NB (1990) Hep‑G2 cells as a resource for metabolic studies ‑ lipoprotein,
cholesterol, and bile‑acids. FASEB J 4(2):161–168
Johansson M, Bielenstein M (1994) Determination of 4‑hydroxycyclophospha‑
mide in plasma, as 2,4‑dinitrophenylhydrazone derivative of aldophos‑
phamide, by liquid‑chromatography. J Chromatogr B 660(1):111–120.
Nicolas I, Bijani C, Brasseur D, Pratviel G, Bernadou J, Robert A (2013) Metal‑
loporphyrin‑catalyzed hydroxylation of the N, N‑dimethylamide function
of the drug molecule SSR180575 to a stable N‑methyl‑N‑carbinolamide.
Nouri‑Nigjeh E, Permentier HP, Bischof R, Bruins AP (2010) Lidocaine oxidation
by electrogenerated reactive oxygen species in the light of oxidative
Ohtani T, Nakamura T, Toda K, Furukawa F (2006) Cyclophosphamide enhances
TNF‑alpha‑induced apoptotic cell death in murine vascular endothe‑
Olsavsky KM, Page JL, Johnson MC, Zarbl H, Strom SC, Omiecinski CJ (2007)
Gene expression profling and diferentiation assessment in primary
human hepatocyte cultures, established hepatoma cell lines, and
human liver tissues. Toxicol Appl Pharmacol 222(1):42–56. https://doi.
Omole JG, Ayoka OA, Alabi QK, Adefsayo MA, Asafa MA, Olubunmi BO, Fadeyi
BA (2018) Protective efect of kolaviron on cyclophosphamide‑induced
cardiac toxicity in rats. J Evid Based Integr Med 23:1–11. https://doi.
Park BK, Boobis A, Clarke S, Goldring CE, Jones D, Kenna JG, Lambert C, Laverty
HG, Naisbitt DJ, Nelson S, Nicoll‑Grifth DA, Obach RS, Routledge P,
Smith DA, Tweedie DJ, Vermeulen N, Williams DP, Wilson ID, Baillie TA
(2011) Managing the challenge of chemically reactive metabolites in
drug development. Nat Rev Drug Discov 10(4):292–306. https://doi.
Pervaiz I, Ahmad S, Madni MA, Ahmad H, Khaliq FH (2013) Microbial biotrans‑
formation: a tool for drug designing (Review). Prikl Biokhim Mikrobiol
Peter G, Hohorst HJ (1979) Synthesis and preliminary antitumor evaluation
of 4‑(SR)‑sulfdo‑cyclophosphamides. Cancer Chemother Pharmacol
Piera J, Baeckvall JE (2008) Catalytic oxidation of organic substrates by molecu‑
lar oxygen and hydrogen peroxide by multistep electron transfer—a
biomimetic approach. Angew Chem Int Ed 47(19):3506–3523
Poraj‑Kobielska M, Atzrodt J, Holla W, Sandvoss M, Grobe G, Scheibner K,
Hofrichter M (2013) Preparation of labeled human drug metabolites and
drug‑drug interaction‑probes with fungal peroxygenases. J Labelled
Poraj‑Kobielska M, Kinne M, Ullrich R, Scheibner K, Kayser G, Hammel KE,
Hofrichter M (2011) Preparation of human drug metabolites using
fungal peroxygenases. Biochem Pharmacol 82(7):789–796. https://doi.
Prados J, Melguizo C, Rama AR, Ortiz R, Segura A, Boulaiz H, Velez C, Caba O,
Ramos JL, Aranega A (2010) Gef gene therapy enhances the therapeutic
efcacy of doxorubicin to combat growth of MCF‑7 breast cancer cells.
Kars MD, Iseri OD, Gunduz U, Ural AU, Arpaci F, Molnar J (2006) Development
of rational in vitro models for drug resistance in breast cancer and modu‑
lation of MDR by selected compounds. Anticancer Res 26(6B):4559–4568
Kiebist J, Hofrichter M, Zuhse R, Scheibner K (2019) Oxyfunctionalization
of pharmaceuticals by fungal peroxygenases. In: Grunwald P (ed)
Pharmaceutical Biocatalysis: Chemoenzymatic of Active Pharmaceutical
Ingredients, vol 1. Jenny Stanford Publishing Pte Ltd, Singapore
Kiebist J, Holla W, Heidrich J, Poraj‑Kobielska M, Sandvoss M, Simonis R, Grobe
G, Atzrodt J, Hofrichter M, Scheibner K (2015) One‑pot synthesis of
human metabolites of SAR548304 by fungal peroxygenases. Bioorg Med
Kiebist J, Schmidtke KU, Zimmermann J, Kellner H, Jehmlich N, Ullrich R,
Zander D, Hofrichter M, Scheibner K (2017) A peroxygenase from Chaeto-
mium globosum catalyzes the selective oxygenation of testosterone.
Kinne M, Poraj‑Kobielska M, Aranda E, Ullrich R, Hammel KE, Scheibner K, Hof‑
richter M (2009) Regioselective preparation of 5‑hydroxypropranolol and
4’‑hydroxydiclofenac with a fungal peroxygenase. Bioorg Med Chem Lett
Kirchmair J, Göller AH, Lang D, Kunze J, Testa B, Wilson ID, Glen RC, Schneider
G (2015) Predicting drug metabolism: experiment and/or computation?
Knowles BB, Howe CC, Aden DP (1980) Human hepatocellular carcinoma cell
lines secrete the major plasma proteins and hepatitis B surface antigen.
Li J, Xu LZ, He KL, Guo WJ, Zheng YH, Xia P, Chen Y (2001) Reversal efects of
nomegestrol acetate on multidrug resistance in adriamycin‑resistant
MCF7 breast cancer cell line. Breast Cancer Res 3(4):253–263. https://doi.
Litvinas ND, Brodsky BH, Du Bois J (2009) C‑H hydroxylation using a heterocy‑
clic catalyst and aqueous H2O2. Angew Chem Int Ed 48(25):4513–4516.
Low JE, Borch RF, Sladek NE (1982) Conversion of 4‑Hydroperoxycyclo‑
phosphamide and 4‑Hydroxycyclophosphamide to Phosphoramide
Mustard and Acrolein Mediated by Bifunctional Catalysts. Cancer Res
42(3):830–837
Madsen KG, Olsen J, Skonberg C, Hansen SH, Jurva U (2007) Development and
evaluation of an electrochemical method for studying reactive phase‑I
metabolites: correlation to in vitro drug metabolism. Chem Res Toxicol
Masood MA, Farrant E, Morao I, Bazin M, Perez M, Bunnage ME, Fancy SA, Peak‑
man T (2012) Lead diversifcation. Application to existing drug molecules:
Mifepristone 1 and antalarmin 8. Bioorg Med Chem Lett 22(1):723–728.
Mitra R, Guo Z, Milani M, Mesaros C, Rodriguez M, Nguyen J, Luo X, Clarke D,
Lamba J, Schuetz E, Donner DB, Puli N, Falck JR, Capdevila J, Gupta K, Blair
IA, Potter DA (2011) CYP3A4 mediates growth of estrogen receptor‑
positive breast cancer cells in part by inducing nuclear translocation of
phospho‑Stat3 through biosynthesis of (+/‑)‑14,15‑epoxyeicosatrienoic
Ren S, Yang JS, Kalhorn TF, Slattery JT (1997) Oxidation of cyclophosphamide
to 4‑hydroxycyclophosphamide and deschloroethylcyclophosphamide
in human liver microsomes. Cancer Res 57(19):4229–4235
Rodriguez‑Antona C, Ingelman‑Sundberg M (2006) Cytochrome P450
pharmacogenetics and cancer. Oncogene 25(11):1679–1691. https://doi.
Sawayama AM, Chen MM, Kulanthaivel P, Kuo MS, Hemmerle H, Arnold FH
(2009) A panel of cytochrome P450 BM3 variants to produce drug
metabolites and diversify lead compounds. Chem‑Eur J 15(43):11723–
Schadt S, Bister B, Chowdhury SK, Funk C, Hop CE, Humphreys WG, Igarashi F,
James AD, Kagan M, Khojasteh SC (2018) A decade in the MIST: learnings
from investigations of drug metabolites in drug development under the
“metabolites in safety testing”regulatory guidance. Drug Metab Dispos
46(6):865–878
Molina‑Espeja P, Garcia‑Ruiz E, Gonzalez‑Perez D, Ullrich R, Hofrichter M,
Alcalde M (2014) Directed evolution of unspecifc peroxygenase from
Agrocybe aegerita. Appl Environ Microbiol 80(11):3496–3507. https://doi.
Molina‑Espeja P, Ma S, Mate DM, Ludwig R, Alcalde M (2015) Tandem‑yeast
expression system for engineering and producing unspecifc peroxyge‑
Nedderman AN (2009) Metabolites in safety testing: metabolite identifca‑
tion strategies in discovery and development. Biopharm Drug Dispos
Scharer OD (2005) DNA interstrand crosslinks: natural and drug‑induced
DNA adducts that induce unique cellular responses. ChemBioChem
Schroer K, Kittelmann M, Lutz S (2010) Recombinant human cytochrome
P450 monooxygenases for drug metabolite synthesis. Biotechnol Bioeng